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Abstract: The prevalence of co-morbidities among patients with Chronic Obstructive Pulmonary
Disease (COPD) is well documented in the literature. Therefore, this pilot study aimed to
identify whether co-morbidities screening would enhance COPD case-finding. Smoking patients
were approached at Croydon University Hospital and two local community pharmacies (CPs).
Their co-morbidities, respiratory symptoms, smoking pack-years and exercise capacity were collected.
Airflow limitation was determined using handheld spirometry (COPD-6) device. The prevalence of
airflow limitation was 42% (n = 21/50). The main identified predictors of airflow limitation were:
co-morbidities (OR = 9, CI: 1.04–77.81, p = 0.025), respiratory symptoms (OR = 33.54, CI: 1.06–11.77,
p = 0.039) and smoking history of ≥20 pack-years (OR = 3.94, CI: 1.13–13.64, p = 0.029). CPs were the
main location for case-finding. This study demonstrated the need to screen for co-morbidities for
COPD case-finding within CPs.
Keywords: Chronic Obstructive Pulmonary Disease (COPD), airflow limitation; co-morbidities;
smoking; primary care
1. Introduction
Chronic Obstructive Pulmonary Disease (COPD) is underdiagnosed in many countries [1].
In the UK, 3 million people are estimated to have COPD with only 900,000 diagnosed [2]. Smoking is the
main risk factor for COPD development [1,3,4]. Unfortunately, patients are usually in a more advanced
stage when the disease is brought to clinical attention [3]. The prevalence of co-morbidities such
as diabetes, cardiovascular diseases, anxiety and depression among COPD patients is well documented
in the literature [5]. These co-morbidities markedly affect health outcomes in COPD [5] including
mortality and morbidity [6]. Increasing evidence in the literature suggests a link between COPD and
these co-morbidities which are considered to be a part of the commonly prevalent non-pulmonary
sequelae of the condition due to the presence of chronic systemic inflammation [7,8].
In Croydon, the proposed estimated prevalence of COPD is 4.6%. However, general practice
records indicate a prevalence of 0.7%, demonstrating under-diagnosis [9]. The cost of COPD hospital
admission is estimated to be £3695 [9] compared to the national average cost in England of £1960 [10].
Hence, a COPD strategy was launched in Croydon to enhance diagnosis, support to patients and
reduce hospital admissions [9].
This pilot study aimed to identify whether co-morbidities detection could enhance COPD
diagnosis using handheld spirometer (COPD-6 device) in chronic smokers in Croydon.
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2. Materials and Methods
2.1. Participants and Recruitment
Patients were approached at Croydon University Hospital (CUH) and two community pharmacies
(CPs) in Croydon, from January to April 2016. Patients aged between 35 and 70, who had smoking
history of more than 10 pack-years and were medically fit to perform the COPD-6 test were included.
Patients with any of the following (contraindications for COPD-6 test) were excluded: uncontrolled
blood pressure, aneurysm (not treated), ear infection or perforation of the ear drum, eye problems
(glaucoma), dementia, pregnancy, current or recent respiratory infection and/or taking antibiotics or
prednisolone within the last 6 weeks, unwell (nausea, vomiting or pain); or if they suffered from any of
the following within the last 3 months: collapsed lung (pneumothorax), haemoptysis of unknown cause,
myocardial infarction or unstable cardiac condition, abdominal, chest, ear or eye surgery, blood clot on
the lung (pulmonary embolus), stroke. Patients were also excluded if they were already diagnosed
with asthma or COPD.
2.2. Questionnaire
Data collection was conducted using a short paper-based questionnaire. The questionnaire
was designed to elicit information about: patient’s details, respiratory symptoms, pack-years
smoking history, medical history, COPD-6 test and history of co-morbidities (Appendix A). In addition,
patients’ exercise capacity was assessed using the Medical Research Council (MRC) breathlessness
scale [11].
Following the completion of the questionnaire, patients were asked to perform the forced
expiratory manoeuvre for at least six seconds using the handheld spirometer COPD-6 device.
Patients were asked to do at least two acceptable measurements and those with ratio of FEV1/FEV6
< 0.75 were considered to have possible airflow obstruction/limitation [12].
2.3. Data Analysis
The data was entered into Microsoft Excel. Odds ratios were calculated to measure the association
of a variable with airflow limitation. Barnard’s Exact Test was used to test the statistical significance
difference of variables and of the odds ratio not equalling 1. The level of significance was set at p < 0.05.
2.4. Ethical Consideration
Ethical approval was granted by the Kingston University Delegated Research Ethics Committee
(Reference No. 1213/045).
3. Results
3.1. Participants’ Characteristics
Total of 264 patients were approached; 214 patients were excluded and 50 patients were included
and performed the COPD-6 test (Figure 1). Participants’ characteristics are summarised in Table 1.
Pharmacy 2018, 6, 45 3 of 7
Pharmacy 2017, 5, x FOR PEER REVIEW  3 of 7 
 
 
Figure 1. Participants recruitment: total number of patients approached during the study (n = 264). 
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Age, years (median) 53 56  
Age ≥ 60, n (%) 8 (28%) 9 (43%) 
0.336 Age < 60, n (%) 21 (72%) 12 (57%) 
Female gender, n (%) 19 (66%) 11 (52%) 
0.371 Male gender, n (%) 10 (34%) 10 (48%) 
Smoking history, pack-years - -  
<20, n (%) 16 (55%) 5 (24%) 
0.029 ≥20, n (%) 13 (45%) 16 (76%) 
Respiratory symptoms, n (%) 
MRC breathlessness grade ≥3 12 (41%) 15 (71%) 0.039 
Presence of co-morbidities, n (%) 20 (69%) 20 (95%) 0.025 
3.2. COPD-6 Screening 
42% of patients (n = 21/50) had a ratio of FEV1/FEV6 < 0.75 and considered to have possible 
airflow limitation (Table 1). The majority of those with airflow limitation had an MRC breathlessness 
score of grade 3 or above (71%, n = 15/21) (p = 0.039). Besides smoking, the only demographic factor 
that was significantly different between the two groups was the presence of co-morbidities (p = 
0.025). The co-morbidities present in each group are summarised in Table 2. 
  
Figure 1. Participants recruitment: total number of patients approached during the study (n = 264).
Table 1. Participants demographics, clinical characteristics and airflow limitation (n = 50).
Variables No Airflow Limitation(n = 29)
Have Airflow
Limitation (n = 21) p-Values
Age, years (median) 53 56
Age ≥ 60, n (%) 8 (28%) 9 (43%)
0.336Age < 60, n (%) 21 (72%) 12 (57%)
Female gender, n (%) 19 (66%) 11 (52%)
0.371gender, n (%) 10 (34%) 10 (48%)
Smoki history, pack-years - -
<20, n (%) 16 (55%) 5 (24%)
0.029≥20, n (%) 13 (45%) 16 (76%)
Respiratory symptoms, n (%)
MRC breathlessness grade ≥3 12 (41%) 15 (71%) 0.039
Presence of co-morbidities, n (%) 20 (69%) 20 (95%) 0.025
3.2. COPD-6 Screening
42% of patients (n = 21/50) had a ratio of FEV1/FEV6 < 0.75 and considered to have possible
airflow limitation (Table 1). The majority of those with airflow limitation had an MRC breathlessness
score of grade 3 or above (71%, n = 15/21) (p = 0.039). Besides smoking, the only demographic factor
that was significantly different between the two groups was the presence of co-morbidities (p = 0.025).
The co-morbidities present in each group are summarised in Table 2.
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Table 2. Breakdown of co-morbidities within the recruited sample.
Co-Morbidity No Airflow Limitation (n = 29) Have Airflow Limitation (n = 21)
Hypertension (HTN), n (%) 4 (14%) 9 (43%)
Cardiovascular diseases, n (%) 3 (10%) 5 (24%)
Hyperlipidaemia, n (%) 7 (24%) 4 (19%)
Depression, n (%) 5 (17%) 10 (48%)
Diabetes, n (%) 4 (14%) 4 (19%)
Osteoporosis, n (%) 2 (7%) 3 (14%)
Peripheral Vascular Disease (PVD), n (%) 6 (21%) 3 (14%)
Patients were approached at the main outpatient department and the smoking cessation clinic
at CUH, in addition to CPs. Considering the time spent in each location, 1 patient per day was screened
positive in CPs compared to 1 patient per 3 days and 4 days in the main outpatient department and
smoking cessation clinic respectively.
3.3. Predictive Factors of Airflow Limitation
The median smoking history was 25 pack-years among patients having airflow limitation,
with 67% (n = 14/21) still actively smoking. Smoking history of ≥20 pack-years had an odds ratio of
3.94 (CI: 1.13–13.64) in predicting airflow limitation.
Co-morbidities were prevalent in most patients (95%, n = 20/21) with airflow limitation.
Nearly two-third of the patients (62%, n = 13/21) had two or more co-morbidities. The odds to
have airflow limitation in patients with co-morbidities was 9 (CI: 1.04–77.81).
The majority of patients with airflow limitation had early respiratory symptoms. The presence
of such symptoms had an odds ratio of 3.54 (CI: 1.06–11.77) in predicting airflow limitation (Table 3).
Only 26.6% (n = 4/15) have reported the symptoms to their general practitioner (GP); two out of the
four who reported their symptoms have performed spirometry.
Table 3. Predictors of airflow limitations in smokers.
Predictors of Airflow Limitation in Smokers (n = 50)
Independent variables Odds ratio (95% CI)
Age ≥ 60 1.97 (0.600–6.45)
Gender (male) 1.72 (0.55–5.45)
Smoking history ≥ 20 pack-years 3.94 (1.13–13.64)
Presence of respiratory symptoms 3.54 (1.06–11.77)
Presence of co-morbidities 9 (1.04–77.81)
4. Discussion
In this study, the prevalence of airflow limitation was 42%. However, all patients that were
identified to have airflow limitation will need to perform standard spirometry test to confirm diagnosis.
In Ching et al. [13] study, the prevalence of airflow limitation using the handheld spirometry was 10.6%,
but when airflow limitation was confirmed with spirometry, the prevalence was 6%. Following the
analogy of Ching et al. [13] study, the corrected prevalence of airflow limitation would be reduced
from 42% to 23.8%. Consequently, 12 of the 21 patients who screened positive with the handheld
spirometry will be confirmed to have COPD.
CPs were found to be suitable premises for COPD screening in the current study. The positive
role of community pharmacists in early detection/screening of COPD has been already emphasized in
the literature [14,15]. A pilot study in the UK showed that community pharmacy COPD-screening
could save the NHS £264 million [15].
Parameters such as age, smoking history and early respiratory symptoms, have been already
identified and used to aid in COPD screening [16]. However, the current study identified co-morbidities
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as an additional significant predictor (p = 0.025) to COPD detection/screening. Despite that the majority
of patients with airflow limitation had early respiratory symptoms. Yet only four patients reported this
to their GP, and only two performed spirometry. This highlights the need to enhance public awareness
about these symptoms, as a comprehensive approach to their management. It also highlights the
need to raise awareness among healthcare professionals about the importance of investigating these
reported symptoms and performing spirometry testing as appropriate.
The current study is a pilot study with small sample size which limits the generalisability of
the results. In addition, the study employed a self-administered questionnaire thus the data collected
was self-reported which is another limitation.
5. Conclusions
The current study, although limited by a small sample size, demonstrated the need to consider
co-morbidities as a primary screening parameter for COPD in the efforts of Croydon to optimise
early diagnosis. The study also highlighted that CPs can provide a suitable venue for early screening
of COPD.
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Appendix A Study Questionnaire
Co-morbidity screening sheet
Name:
Date Of Birth:
Age:
Phone number:
Ward:
Background:
Have you noticed increasing breathlessness, chronic cough, sputum production, or wheeze over
the last few years? Y/N
Having noticed these symptoms. Did you seek medical advice? Y/N
When medical advice sought, were you asked to perform spirometry? Y/N
Any comments?
Height:
MRC: 1/2/3/4/5
Smoking status: Y/N
Pack years:
Comorbidity:
Ischaemic Heart Disease (IHD)/Angina: Y/N
Pulmonary Hypertension: Y/N
Peripheral Vascular Disease (PVD): Y/N
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Diabetes: Y/N
Cardiovascular Disease (CVD): Y/N
Osteoporosis: Y/N
Hyperlipidaemia: Y/N
Depression: Y/N
Others:
Medical history:
Current or suspected respiratory infection Y/N
Any antibiotics/prednisolone within the last 6 weeks Y/N
Aneurysm (not treated) Y/N
Unwell today, i.e., nausea, vomiting or pain Y/N
Uncontrolled blood pressure Y/N
Communication problems, i.e., dementia Y/N
Ear problems, i.e., ear infection Y/N
Eye problems, i.e., glaucoma Y/N
Pregnancy Y/N
Any of the following within the last 3 months:
Collapsed lung Y/N
Haemoptysis of unknown cause Y/N
Myocardial infarction or unstable heart
condition
Y/N
Abdominal, chest, ear or eye surgery Y/N
PE or Blood clot on the lung Y/N
Stroke Y/N
Fit for spirometry? Y/N.
COPD6 Test:
FEV1 FEV1% Pred FEV6 FEV6% Pred Ratio
Effort 1
Effort 2
Effort 3
Refer to spirometry team for follow up? Y/N
Any comments:
PATIENT NAME: SIGNATURE: DATE:
CLINICIAN NAME: SIGNATURE DATE:
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